investing.comSEP 11 min read$TEM

Tempus AI stock rises on Piper Sandler upgrade to Overweight

Tempus AI Inc (TEM) shares rose 2.1% premarket after Piper Sandler upgraded it to Overweight with a $76 price target. Analyst David Westenberg cited three growth drivers, including the pending Personalis acquisition and FDA approval of tumor-only xT CDx. The previous Neutral rating was due to AI sentiment driving valuation.

Original reporting

investing.com

Published Sep 1, 2026, 12:48 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 1, 2026, 1:01 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefMarket movers

Primary signal

$TEM

Bullish

high confidence

Mentioned

$TEM

Relevance

7/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$TEMBullishMed

Why it matters

The upgrade highlights new growth levers, potentially re‑rating the stock.

Market read

Analyst upgrade with a higher price target is a fresh catalyst that can move the stock in the near term.

What to watch

Execution risk of the Personalis acquisition and regulatory timelines for xT CDx.

Relevance 7/10Novelty 7/10Timing: premarket today

Background

Tempus AI is a diagnostics and data company focusing on AI‑driven tumor sequencing.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMBullishHigh confidence

Context

Piper Sandler upgraded Tempus AI to Overweight and raised price target to $76, driving a 2.1% pre‑market rise.

Expected impact

Potential further upside toward the $76 target in the short term.

Evidence & confidence

Upgrade includes concrete growth drivers and a 35% target increase, indicating material catalyst.

Market effects

Sector

Positive sentiment may lift other AI‑driven diagnostics firms.

Regional

U.S. biotech/health‑tech sector could see modest gains.

Global

Limited to investors tracking AI‑enabled healthcare stocks.

Counterpoint

What could challenge this read

Upgrade may be premature if integration of Personalis faces delays.

Key entities

Analyst
Piper Sandler
Equity research firm that issued the upgrade.
Target Company
Personalis
Acquisition target providing a tumor‑informed MRD platform.

Read at source ← All news

SEP 22

$TEMMedAI 8/10

Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test

Goldman Sachs initiated Tempus AI (TEM) with a Neutral rating and $75 target. Q2 revenue rose 22% YoY to $382.5M, with Diagnostics up 20% and Data/Applications up 28%. Tempus extended its partnership with Recursion (RXRX) through 2029. FDA approvals could boost future revenue. Short interest is high at 29.17% of float.

insidermonkey.com2 min

SEP 17

$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min

SEP 17

$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min

SEP 15

$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min

SEP 5

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min

SEP 2

$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min